Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Next Previous
X
Search
Trial Profile

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms NEPTUNES

    • Most Recent Events

    • 04 Jun 2024 Results(Between May 2018 and June 2022 , n=119) reporting a phase 2 trial of two different dose schedules for nivolumab (NIVO) + ipilimumab (IPI) in patients and expecting dose schedule and biomarker should now be tested in a phase 3 clinical trial, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 28 Jun 2022 The protocol was amended to add a new cohort of patients receiving Nivolumab 3 mg/kg and ipilimumab 1 mg/kg every three weeks for a maximum of 4 doses with a 3 week gap after last combination dose, according to ClinicalTrials.gov record. Accordingly, the patient number was changed to 380.
    • 28 Jun 2022 Planned End Date changed from 1 Jul 2025 to 1 Jun 2027.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top